company_name,website_timestamp,preclinical_stage,drug_molecule,target,therapeutic_area,target_type,development_stage,small_molecules,small_molecules_keyword,small_molecules_source_url,peptides,peptides_keyword,peptides_source_url,proteins,proteins_keyword,proteins_source_url,antibodies,antibodies_keyword,antibodies_source_url,antibody_conjugates,antibody_conjugates_keyword,antibody_conjugates_source_url,fusion_proteins,fusion_proteins_keyword,fusion_proteins_source_url,nucleic_acid_therapeutics,nucleic_acid_therapeutics_keyword,nucleic_acid_therapeutics_source_url,gene_cell_therapies,gene_cell_therapies_keyword,gene_cell_therapies_source_url,vaccines,vaccines_keyword,vaccines_source_url,protein_degraders,protein_degraders_keyword,protein_degraders_source_url,other_modalities,other_modalities_keyword,other_modalities_source_url
carsgen therapeutics ltd,2025-08-14 20:15:00,Yes,Zevorcabtagene Autoleucel; Satricabtagene Autoleucel; CT0596; KJ-C2219; KJ-C2320; KJ-C2114; KJ-C2526,"BCMA, B-cell maturation antigen; CLDN18.2, Claudin 18.2; CD19/CD20; CD38; NKG2DL",oncology; hematologic malignancies; autoimmune diseases,immune checkpoint; other; gpcr; other; other,Approved; NDA/BLA; Phase 1; Phase 1; Phase 1; Phase 1; Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,CAR T-cell therapies,https://www.carsgen.com/,Yes,mRNA cancer vaccine in combination with CAR T,https://www.biospace.com/employer/543068/carsgen-therapeutics,No,,,No,,
